4.6 Article

PARP inhibition in UV-associated angiosarcoma preclinical models

Journal

JOURNAL OF CANCER RESEARCH AND CLINICAL ONCOLOGY
Volume 147, Issue 9, Pages 2579-2590

Publisher

SPRINGER
DOI: 10.1007/s00432-021-03678-4

Keywords

Angiosarcoma; Subtype; PARP; Temozolomide; Combination treatment; SLFN11

Categories

Funding

  1. Dutch charities Stichting Bergh in het Zadel voor de Kankerbestrijding

Ask authors/readers for more resources

Angiosarcoma (AS) is a rare vasoformative sarcoma with poor prognosis, especially when related to UV exposure. This study investigated the expression of PARP1 and SLFN11 in UV AS, and found that combination treatment of PARPi olaparib and TMZ showed synergistic effects in inducing apoptosis and DNA damage in UV AS cell lines, suggesting a potential novel treatment option for UV AS patients.
Purpose Angiosarcoma (AS) is a rare vasoformative sarcoma, with poor overall survival and a high need for novel treatment options. Clinically, AS consists of different subtypes, including AS related to previous UV exposure (UV AS) which could indicate susceptibility to DNA damage repair inhibition. We, therefore, investigated the presence of biomarkers PARP1 (poly(ADP-ribose)polymerase-1) and Schlafen-11 (SLFN11) in UV AS. Based on experiences in other sarcomas, we examined (combination) treatment of PARP inhibitor (PARPi) olaparib and temozolomide (TMZ) in UV AS cell lines. Methods Previously collected UV AS (n = 47) and non-UV AS (n = 96) patient samples and two UV AS cell lines (MO-LAS and AS-M) were immunohistochemically assessed for PARP1 and SLFN11 expression. Both cell lines were treated with single agents PARPi olaparib and TMZ, and the combination treatment. Next, cell viability and treatment synergy were analyzed. In addition, effects on apoptosis and DNA damage were examined. Results In 46/47 UV AS samples (98%), PARP1 expression was present. SLFN11 was expressed in 80% (37/46) of cases. Olaparib and TMZ combination treatment was synergistic in both cell lines, with significantly increased apoptosis compared to single agent treatment. Furthermore, a significant increase in DNA damage marker gamma H2AX was present in both cell lines after combination therapy. Conclusion We showed combination treatment of olaparib with TMZ was synergistic in UV AS cell lines. Expression of PARP1 and SLFN11 was present in the majority of UV AS tumor samples. Together, these results suggest combination treatment of olaparib and TMZ is a potential novel AS subtype-specific treatment option for UV AS patients.

Authors

I am an author on this paper
Click your name to claim this paper and add it to your profile.

Reviews

Primary Rating

4.6
Not enough ratings

Secondary Ratings

Novelty
-
Significance
-
Scientific rigor
-
Rate this paper

Recommended

No Data Available
No Data Available